Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Jul;13(4):642-645.
doi: 10.1111/cts.12797. Epub 2020 May 9.

Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection

Samuel L M Arnold  1 , Frederick Buckner  1
Affiliations
Comment

Hydroxychloroquine for Treatment of SARS-CoV-2 Infection? Improving Our Confidence in a Model-Based Approach to Dose Selection

Samuel L M Arnold et al. Clin Transl Sci. 2020 Jul.
No abstract available

PubMed Disclaimer

Conflict of interest statement

All authors declared no competing interests for this work.

Figures

Figure 1
Figure 1
Time course of simulated unbound HCQ lung trough concentrations relative to in vitro efficacy data with varying HCQ lung K p values. HCQ lung concentrations were simulated with varying HCQ lung K p values after HCQ dosing of 400 mg b.i.d. for 1 day followed by 200 mg b.i.d. for 4 days or 200 mg t.i.d. for 10 days. The HCQ‐simulated concentrations were used to calculate the 90% confidence intervals, and the fifth percentile was used to determine the ratio of unbound HCQ lung trough concentrations to the EC50 (R_EC50) (a) and minimum concentration required to eliminate SARS‐CoV‐2 in vitro (R_Max) (b).
See this image and copyright information in PMC

Comment on

References

    1. Guan, W.J. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 382, 1708–1720 (2020). - PMC - PubMed
    1. Gao, J. , Tian, Z. & Yang, X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID‐19 associated pneumonia in clinical studies. Biosci. Trends. 14, 72–73 (2020). - PubMed
    1. Yao, X. et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). Clin. Infect. Dis. 2020. 10.1093/cid/ciaa237 - DOI - PMC - PubMed
    1. Gautret, P. et al. Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label non‐randomized clinical trial. Int. J. Antimicrob. Agents. 2020. 10.1016/j.ijantimicag.2020.105949 - DOI - PMC - PubMed
    1. Wallace, D.J. , Gudsoorkar, V.S. , Weisman, M.H. & Venuturupalli, S.R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat. Rev. Rheumatol. 8, 522–533 (2012). - PubMed

Substances

LinkOut - more resources